Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations

MLA

Kavita V. Nair, et al. “Categorization of Infliximab Dose Changes and Healthcare Utilization and Expenditures for Patients with Rheumatoid Arthritis in Commercially Insured and Medicare-Eligible Populations.” Current Medical Research and Opinion, vol. 25, no. 2, Feb. 2009. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....44456031596fbd95cd3f6af794fd39ec&authtype=sso&custid=ns315887.

APA

Kavita V. Nair, Ahmad Naim, Mirza Rahman, Vicki Zhang, Jill Van Den Bos, B Tang, & Joseph J. Saseen. (2009). Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Current Medical Research and Opinion, 25(2).

Chicago

Kavita V. Nair, Ahmad Naim, Mirza Rahman, Vicki Zhang, Jill Van Den Bos, B Tang, and Joseph J. Saseen. 2009. “Categorization of Infliximab Dose Changes and Healthcare Utilization and Expenditures for Patients with Rheumatoid Arthritis in Commercially Insured and Medicare-Eligible Populations.” Current Medical Research and Opinion 25 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....44456031596fbd95cd3f6af794fd39ec&authtype=sso&custid=ns315887.